OxyNorm capsules - Medsafe
OxyNorm® capsules 5mg. 10mg, 20mg Mfcoxyno10914 1 OxyNorm® capsules Oxycodone hydrochloride (ox-ee-code-own hi-dro-klor …
Download OxyNorm capsules - Medsafe
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Opioid Dose Equivalence - ANZCA
fpm.anzca.edu.auPractical Considerations 1) This opioid dose equivalence table is intended for comparison of different opioid regimens in individual patients or in patient cohorts. 2) Caution is required if opioid dose equivalence tables are used to guide opioid switching, as the administration of a calculated‘equivalent’ dose of the replacement …
ANTALGIQUES DU PALIER III (MORPHINIQUES FORTS)
www.antalvite.frwww.antalvite.fr ANTALGIQUES DU PALIER III (MORPHINIQUES FORTS) Produits Délai d’action Pic d’action Intervalle d’administration Précautions d’emploi
LES PRINCIPAUX MÉDICAMENTS ANTALGIQUES
www.antalvite.frwww.antalvvite.fr les principaux mÉdicaments antalgiques antalgiques palier i antalgiques palier ii antalgiques palier iii adjuvants le
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET OxyNorm® Capsules & Oral Liquid (OXYNORM011) 29 June 2017 Page 3 of 14 Method of administration OXYNORM capsules should be swallowed whole and not opened, chewed or crushed.
PRINCIPAUX OPIOÏDES FORTS SOURCES …
www.sfap.orgTable pratique d’équiantalgie des opioïdes forts dans la douleur cancéreuse par excès de nociception (ratio calculé à partir du passage par la morphine orale) 1 morphine orale = 1/2 morphine SC = 1/3 morphine IV - Délais action approximatifs de morphine LI : Per os : 40 mn, SC : 20 mn, IV : 10 mn.
ABHB Prescribing Guideline Use of Oxycodone - …
www.wales.nhs.ukThis Guidance should be used in conjunction with the Summary of Product Characteristics (SmPC) for the particular formulation of oxycodone being used.
090714 opioid conversions - © palliativedrugs.com
www.palliativedrugs.comChoice of opioid This is obviously dependent on the individual patient, but as a general rule, use: • Morphine as first line opioid via oral and subcutaneous routes